Bone Marrow Transplantation News

John Theurer Cancer Center at Hacksensack University Cancer Center announced the appointment of five physicians to its medical staff.

A randomized phase 3 study designed to evaluate itacitinib for patients with treatment-naive acute graft-versus-host disease failed to meet its primary and key secondary endpoints, according to the agent’s manufacturer.

ASH announced the recipients of its 2019 Scholar Awards.

ORLANDO — Blinatumomab demonstrated superiority over chemotherapy as post-reinduction consolidation prior to hematopoietic stem cell transplantation among children and young adults with B-acute lymphoblastic leukemia in intermediate- or high-risk first relapse, according to results of the Children’s Oncology Group Study AALL1331 presented during the late-breaking abstract session of ASH Annual Meeting and Exposition.

ORLANDO — Allogeneic hematopoietic stem cell transplantation appeared effective and generally safe for patients with relapsed or refractory classical Hodgkin lymphoma who received prior immune checkpoint inhibitor therapy, according to retrospective study results presented at ASH Annual Meeting and Exposition.

ORLANDO — The use of high-dose post-transplant cyclophosphamide reduced the incidence of severe acute and chronic graft-versus-host disease without affecting risk for relapse among patients undergoing allogeneic hematopoietic stem cell transplant with matched related or unrelated donors, according to results of the randomized phase 3 HOVON-96 study presented during the plenary session of ASH Annual Meeting and Exposition.

ORLANDO — Autologous hematopoietic stem cell transplantation appeared safe and effective for older patients with multiple myeloma, according to study results presented at ASH Annual Meeting and Exposition.

ORLANDO — Genetic alterations at diagnosis predicted OS and leukemia-free survival for older individuals with acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation in first remission, according to study results presented at ASH Annual Meeting and Exposition.

The FDA granted breakthrough therapy designation to abatacept for prevention of moderate to severe acute graft-versus-host disease among individuals who undergo hematopoietic stem cell transplantation from unrelated donors.

Single UM171-expanded cord blood transplantation appeared safe and feasible among a small cohort of patients with hematologic malignancies who lacked suitable HLA-matched donors, according to results of a phase 1/phase 2 study published in The Lancet Haematology.